中国碳青霉烯耐药革兰阴性菌2015至2024年监测趋势
该研究监测2015至2024年中国主要地区医疗机构中碳青霉烯耐药革兰阴性菌的趋势。结果显示肠杆菌目细菌碳青霉烯耐药率除克雷伯菌属外一般低于13%,克雷伯菌属为20.4%至21.9%;多数肠杆菌目对替加环素、黏菌素和多黏菌素B高度敏感,耐药率0.1%至15.4%;美罗培南耐药铜绿假单胞菌检出率连续六年下降,从2018年31.4%降至2024年21.5%;美罗培南耐药鲍曼不动杆菌检出率从2015年64.9%至2024年68.3%。
要点
- 克雷伯菌属碳青霉烯耐药率20.4%至21.9%,高于其他肠杆菌目。
- 美罗培南耐药铜绿假单胞菌检出率连续六年下降,2024年为21.5%。
- 美罗培南耐药鲍曼不动杆菌检出率2024年达68.3%,仍处高位。
核心结论
- 多重耐药菌仍是临床抗感染治疗的重要挑战,需进一步加强细菌耐药监测和抗菌药物合理使用。
主要发现
- 临床肠杆菌目分离株中碳青霉烯耐药率一般低于13%,但克雷伯菌属为20.4%至21.9%。
- 多数临床肠杆菌目分离株对替加环素、黏菌素和多黏菌素B高度敏感,耐药率范围为0.1%至15.4%。
- 美罗培南耐药铜绿假单胞菌检出率连续六年下降,从2018年31.4%降至2024年21.5%。
- 美罗培南耐药鲍曼不动杆菌检出率从2015年64.9%至2024年68.3%,保持较高水平。
临床怎么用
- 临床应关注克雷伯菌属及鲍曼不动杆菌的高碳青霉烯耐药率,结合本地监测数据经验性用药。
- 对肠杆菌目感染,替加环素、黏菌素和多黏菌素B仍保持较高敏感性,可作为参考选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To monitor the trends of carbapenem-resistant gram-negative bacteria to antimicrobial agents in healthcare facilities in major regions of China between 2015 and 2024. METHODS: Carbapenem-resistant gram-negative isolates from 74 hospitals in the country were tested for antimicrobial susceptibility using an automated method (imported or domestic AST instruments) supplemented by the disc diffusion method. Results were evaluated using the 2024 CLSI breakpoint. RESULTS: A total of 339 513 clinical isolates were collected between 2015 and 2024. Among clinical Enterobacterales isolates, the rate of carbapenem resistance was generally below 13%, except for Klebsiella spp., where it ranged from 20.4% to 21.9%. Most clinical Enterobacterales isolates are highly susceptible to tigecycline, colistin, and polymyxin B, with resistance rates ranging from 0.1% to 15.4%. The detection rate of meropenem-resistant Pseudomonas aeruginosa has decreased over six consecutive years, from 31.4% in 2018 to 21.5% in 2024. The detection rate of meropenem-resistant Acinetobacter baumannii remained modest, from 64.9% in 2015 to 68.3% in 2024. CONCLUSIONS: Multidrug-resistant bacteria remain a significant challenge in clinical anti-infective treatment, and the surveillance of bacterial resistance and the rational use of antimicrobial agents need to be further strengthened to combat bacterial resistance.
引用
- Guo Y, Ding L, Zhou Y, et al. Trends of Carbapenem-Resistant Gram-negative Bacteria in China: A Surveillance Study Between 2015 and 2024. J Infect Dis. 2026. PMID: 41824650. doi:10.1093/infdis/jiag083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。